Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
ekrtx.com

See what CB Insights has to offer

Founded Year

2006

Stage

Acquired | Acquired

Total Raised

$160M

About EKR Therapeutics

EKR Therapeutics is a specialty pharmaceutical company committed to serving the acute-care hospital setting by identifying, commercializing, and marketing products to address unmet or undersatisfied medical needs. The company's product offerings include Ready-to-Use CARDENE I.V. (nicardipine hydrochloride), DepoDur (morphine sulfate extended-release liposome injection), and Retavase (reteplase, recombinant).

EKR Therapeutics Headquarter Location

1545 US Highway 206 Third Floor

Bedminster, New Jersey, 07921,

United States

877-435-2524

Latest EKR Therapeutics News

EKR Therapeutics Inc. Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Nov 28, 2016

EKR Therapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 21:46 EST 27 Nov 2016 | BioPortfolio Reports Home » Topics » Biotechnology Business » Latest News » EKR Therapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' EKR Therapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by EKR Therapeutics, Inc. since January 2007. Key Findings Provides intelligence on EKR Therapeutics, Inc. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by EKR Therapeutics, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for EKR Therapeutics, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about EKR Therapeutics, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

EKR Therapeutics Patents

EKR Therapeutics has filed 10 patents.

The 3 most popular patent topics include:

  • Calcium channel blockers
  • Amines
  • Carboxylate esters
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/18/2018

9/1/2020

Amines, Phenols, Piperidines, Calcium channel blockers, Enantiopure drugs

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/18/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/1/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Amines, Phenols, Piperidines, Calcium channel blockers, Enantiopure drugs

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.